Introduced by Sen. Karen Keiser (Kent) (D) on January 24, 2007
To require the purchase of brand name drugs when the cost is below that of the generic brand drug. The bill recognizes that after rebates and coupons are factored in the price of a band name drug, its cost may be lower than the price of a generic brand. If that occurs, the name brand drug should be purchased. See companion HB 1356. Official Text and Analysis.
Referred to the Senate Health & Long-Term Care Committee on January 24, 2007